CD274 and nasopharyngeal carcinoma: EBV-associated malignancies, including NPC, have a high level of PD-L1 (PD-1 ligand) expression—therefore, PD-1/PD-L1 immunotherapies are actively being explored and have shown potential efficacy in refractory/metastatic NPC and other malignancies [79].